Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Zeria Aims at 50% Market Share for Asacol: President Ibe
November 30, 2009
- NDA for Liraglutide, Vildagliptin to Be Reviewed
November 30, 2009
- JDS to Include HbA1c in Its Diagnostic Criteria
November 30, 2009
- Sciele Pharma to Acquire Addrenex: Shionogi
November 30, 2009
- JPMA President Stresses the Need for Price Maintenance System
November 30, 2009
- Rohto Posts Record-High Sales Driven by Cosmetic Business
November 30, 2009
- Blopress Japan's Best-Selling Drug in 2nd Qtr: IMS Japan
November 30, 2009
- FJPWA President Expresses Great Concern about GRU WG's Recommendation
November 30, 2009
- JSA Revises Its GL on Prevention and Management of Asthma
November 30, 2009
- Growth of CRO Business Slows Down due to Megamergers: Mr Nakamura
November 30, 2009
- Non-clinical Evaluation of Anticancer Drugs Reaches Step 4 at ICH
November 30, 2009
- Business Improves for Hospitals and Worsens for GPs, Pharmacies
November 30, 2009
- Toho to Demand Fees to Makers for Services Using Meissa
November 30, 2009
- Chugai's Epogin Applied for Chemotherapy-Induced Anemia
November 30, 2009
- Xolair Recommended in JGL2009
November 30, 2009
- Eisai Launches Sedative-Hypnotic Lusedra in the US
November 30, 2009
- Astellas Applies for ASP8825 for RLS in Japan
November 30, 2009
- Vibativ Launched in the US: Astellas
November 30, 2009
- FDA Warns against Concurrent Use of Omeprazole and Plavix
November 30, 2009
- Alexion Pharma to Hire Up to 13 MCCs in Japan: President Strenger
November 30, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…